ReviewFrontiers in neurology2026
The application progress of artificial intelligence in the diagnosis of Alzheimer's disease.
Review in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder, where traditional diagnostic methods are constrained by limited sensitivity and restricted clinical utility. This review synthesizes recent applications of artificial intelligence (AI) in AD diagnostics, focusing on machine learning (ML) and deep learning (DL) across neuroimaging modalities and multi-omics research. AI algorithms can automatically extract subtle microstructural, metabolic, and molecular features, enabling high-precision classification of AD stages, patient stratification, and non-invasive early screening through multimodal data integration. However, translating AI into routine clinical practice still faces critical challenges, including high equipment costs, insufficient model generalizability across real-world cohorts, data class imbalance, and complex cross-platform standardization barriers. Future research should prioritize cost-effective surrogate modeling, robust multi-center validation, dynamic longitudinal integration, and mechanistic interpretability to accelerate the standardized clinical translation of AI-driven AD diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.